Knight Therapeutics secured exclusive rights to commercialize fostamatinib in Latin America through an agreement with Rigel Pharmaceuticals, Inc. The company plans to launch TAVALISSE® in Mexico in the first half of 2026. This development marks a significant step in expanding treatment options for ITP patients and underscores Knight's commitment to improving patient outcomes across Latin America. Knight Therapeutics Inc. is focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America, with its shares trading on the TSX under the symbol GUD.
Key takeaways:
```html
- Knight Therapeutics Inc. has received regulatory approval from COFEPRIS in Mexico for TAVALISSE® (fostamatinib disodium hexahydrate) to treat thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP).
- TAVALISSE® offers a new therapeutic alternative with an innovative mechanism of action for treating chronic ITP, a condition where the immune system attacks and destroys blood platelets.
- Knight Therapeutics plans to launch TAVALISSE® in Mexico in the first half of 2026, expanding treatment options for ITP patients in Latin America.
- Knight Therapeutics Inc. is a specialty pharmaceutical company focused on commercializing pharmaceutical products in Canada and Latin America, with shares trading on TSX under the symbol GUD.